Detection of ALK and ROS1 fusion gene in lung adenocarcinomas patients and its clinical significance

Abstract

Objective To explore the frequency of ALK and ROS1 fusion genes in lung adenocarcinomas and its correlation with clinicopathologic features. Methods ALK and ROS1 fusion genes from samples of 332 patients with lung adenocarcinomas were detected by fluorescence in situ hybridization.The relationship between ALK, ROS1 fusion genes and clinicopathologic features was analyzed. Results ALK fusion gene was detected in 28 of 332 lung adenocarcinomas samples (8.4%). There was statistical difference in the gender, age, smoking history and clinical stage of patients.13 patients with ROS1 fusion gene were identified among the 332 lung adenocarcinomas samples, which was not correlated with the gender, age, smoking history and clinical stage of patients.None of the cases had concurrent ALK and ROS1 fusion. Conclusions The gene fusion rates of ALK and ROS1 are low in lung adenocarcinomas, and may be defined as special molecular subtype.ALK and ROS1 fusion genes occur more frequently in younger and non-smoking female patients with advanced stage.Genetic testing has important significance to guide clinical targeted therapy. Key words: Lung adenocarcinoma; ALK; ROS1; Fluorescent in situ hybridization